A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European populat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-000045-20

A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The objective of the study is to confirm in a larger and less selected population (?real life conditions?) the positive risk-benefit balance observed with silodosin 8 mg in double-blind, randomised clinical trials. El objetivo del estudio es confirmar en una población más grande y menos seleccionada ("condiciones de vida real") el balance riesgo-beneficio positivo observado con silodosina 8 mg en ensayos clínicos aleatorizados a doble ciego.


Critère d'inclusion

  • benign prostatic hyperplasia,Hiperplasia prostática benigna